Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]